Facial adenocarcinoma treated with intra-arterial chemotherapy  by Chen, Yu-Yuan et al.
JAAD ONLINE
CASE LETTERSFig 1. Facial adenocarcinoma. Before treatment, several
masses on the right cheek.
Fig 2. Facial adenocarcinoma 5 months after treatment
with intra-arterial chemotherapy.Facial adenocarcinoma treated with
intra-arterial chemotherapy
To the Editor: Facial adenocarcinoma is extremely
rare. Treatments include excision, radiotherapy
and chemotherapy.1 We present a case of facial
adenocarcinoma that was successfully treated with
intra-arterial chemotherapy (IAC) after excision and
radiotherapy failed.
A 90-year-oldwomanpresentedwith a nonhealing
2- 3 2-cm ulcer on the right cheek in June 2011.
Biopsy revealed adenocarcinoma. Excision was
recommended, but the patient declined due to her
advanced age and medical comorbidities. Surveys
including computed tomography of chest and
abdomen, gastroduodenoscopy, colonoscopy, and
positron emission tomography revealed no evidence
of visceralmalignancy. Immunohistochemical studies
demonstrated CK 7 ( focal 1), CK20 () S-100 (),
CEA (), vimentin (), GFAP (), actin (), and
p63(1). Apositivep63 stainhad thehighest sensitivity
(96%) for primary adenexal tumors.2 The immuno-
histochemical staining pattern favored a primary
adenocarcinoma, possibly from sweat glands or the
parotid gland. Radiotherapy 5000 cGy in 25 fractions
over 5 weeks was given in July 2011 with a poor
response. The patient underwent wide excision with
histologically negative margins in September 2011.
Tumor recurred 4 months later. She underwent
another 2 excisions, 1 in January and 1 in April 2012.
Tumor was present at the tissue margins following
each excision. The tumor progressed.
The patient was referred for IAC in July 2012
because comorbidities precluded treatment with
systemic chemotherapy. On admission, several
masses (1 3 1 cm to 3 3 2 cm) were noted on the
right cheek (Fig 1).
An implantable port-catheter was inserted
through the right superficial temporal artery into
the external carotid artery with the tip located
proximal to the branching of the facial artery.
Methotrexate 50 mg/day was first infused
continuously for 4 days without any appreciable
effect. Subsequently, 5-fluorouracil (5-FU) infusion
50 mg/day was given in a continuous infusion for
7 days, which was then stopped because of
thrombocytopenia and elevation of GOT/GPT
( grade 2). No other adverse event was noted. The
patient was given a weekly IAC of 5-FU 250 mg until
all tumors disappeared. In total, 21 infusions were
given from August to December 2012.J AM ACAD DERMATOL Open access under CC BY-NC-ND license.The tumors shrank slowly beginning 1 week after
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However, a right side submandibular mass of about
2 3 2 cm was noted incidentally in June 2013.
Computed tomography revealed a cystlike lesion.
The patient and family refused further evaluation of
themass. The size of themass was unchanged during
6 months of follow-up.
IAC has the advantage of delivering a high
concentration of drug to the lesion. Studies by
Harker and Stephen3 showed that a greater con-
centration of 5-FU in the tumor region is achieved
by intra-arterial than by intra-venous administra-
tion. In studies by Claudio et al4 after IAC, 87.5%
of the carcinoma of the facial skin attained
resectability. However, none of the cases was an
adenocarcinoma. IAC has potential for the treat-
ment of refractory neoplasms, and may have
advantages in terms of cosmetic and functional
preservation.
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treatment of neurocysticercosis
To the Editor: Urticarial vasculitis is most often
idiopathic, but may occur in association with
autoimmune disease, malignancy, drugs, or infec-
tion. Parasitic infection is a rare cause of urticarial
vasculitis.1 We report a case of urticarial vasculitis
that resolved after the diagnosis and treatment of
neurocysticercosis.
A 36-year-old Ecuadorian agricultural farmer who
immigrated to the United States 20 years ago
presented with new-onset afebrile seizure. Brain
magnetic resonance imaging (MRI) revealed a ring
enhancing cystic lesion (Fig 1). He also complained
of a 3- to 4-month history of intermittent pruritic
‘‘rash’’ over his back, chest, and arms associated with
a ‘‘burning’’ sensation and ‘‘darkening’’ of skin. On
day 2 of hospitalization he reported worsening
pruritus and new lesions on his thighs.
On exam he had partially blanching, edematous
plaques and scattered erythematous papules on both
posterior thighs. Side lighting revealed urticarial
papules on his thighs and trunk. Hypopigmented
macules were present in a linear distribution on
the dorsal upper extremities, with extensive
excoriations. Skin biopsy of a new urticarial papule
demonstrated early leukocytoclastic vasculitis
(Fig 2), leading to a diagnosis of urticarial vasculitis.
Active urticarial lesions persisted for 4 days.
Labs showedawhite bloodcell count of 123109/L,
normal platelets and complement levels and 0%
eosinophils. Serum antibody testing for toxoplas-
mosis, echinococcosis, cysticercosis, trichinellosis,
histoplasmosis, human immunodeficiency virus,
syphilis, and hepatitis was negative. Cerebrospinal
fluid contained 6white blood cells (83% lymphocytes)
andundetectable levelsof cysticercosis IgGantibodies
with enzyme-linked immunosorbent assay (ELISA).
Neurosurgical removal of the cystic lesion demon-
stratedhyalinizedacellularmaterial composedof focal
parasitic remnants, consistent with the scolex of
deceased parasite. The findings of parasite on brain
biopsy, cystic lesions seenonMRI, and seizure fulfilled
absolute, major, and minor criteria, respectively, for
the diagnosis of neurocysticercosis.2 The patient
was started on albendazole (400 mg twice daily)
and his urticarial vasculitis resolved within a few
days. Two years later he remained seizure-free and
rash-free.
Neurocysticercosis is a leading cause of acquired
epilepsy worldwide.2 Following infection, the
cysticerci of Taenia solium remain viable in the
brain and elicit minimal inflammation.3 Only after
several years when a viable cyst degenerates may the
